In the recent guidelines, addition of SGLT-2 inhibitors to optimal medical therapy is recommended to reduce the risk of CV death and worsening HF in patients with HFrEF, unless SGLT-2 inhibitors are contraindicated or not tolerated [38], [39]. Here, SLC5A2 is linked to hydrops fetalis.